Alteration of striatal dopaminergic neurotransmission in a mouse model of DYT11 myoclonus-dystonia

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Zhang, Lin ^a   Yokoi, Fumiaki ^a   Parsons, Dee S ^b   Standaert, David G ^b   Li, Yuqing ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; SARCOGLYCAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; DYSTONIA; FEMALE; IN VIVO STUDY; KNOCKOUT MOUSE; MICRODIALYSIS; MOUSE; MYOCLONUS; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; WILD TYPE; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECT; DYSTONIC DISORDER; GENETICS; HUMAN; MALE; METABOLISM; MOUSE MUTANT; MYOCLONUS DYSTONIA; PATHOPHYSIOLOGY; PHYSIOLOGY; SYNAPTIC TRANSMISSION; VISUAL CORTEX;

MUS;

AMPHETAMINE; ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DYSTONIC DISORDERS; FEMALE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; SARCOGLYCANS; SYNAPTIC TRANSMISSION; VISUAL CORTEX;

EID: 84863353898     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033669     Document Type: Article

References (43)

1. Fahn S, (1988) Concept and classification of dystonia. Adv Neurol 50: 1-8.
2. Klein C, Brin MF, Kramer P, Sena-Esteves M, de Leon D, et al. (1999) Association of a missense change in the D2 dopamine receptor with myoclonus dystonia. Proc Natl Acad Sci U S A 96: 5173-5176.
3. Zimprich A, Grabowski M, Asmus F, Naumann M, Berg D, et al. (2001) Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus-dystonia syndrome. Nat Genet 29: 66-69.
4. Doheny DO, Brin MF, Morrison CE, Smith CJ, Walker RH, et al. (2002) Phenotypic features of myoclonus-dystonia in three kindreds. Neurology 59: 1187-1196.
5. Misbahuddin A, Placzek M, Lennox G, Taanman JW, Warner TT, (2007) Myoclonus-dystonia syndrome with severe depression is caused by an exon-skipping mutation in the epsilon-sarcoglycan gene. Mov Disord 22: 1173-1175.
6. Grabowski M, Zimprich A, Lorenz-Depiereux B, Kalscheuer V, Asmus F, et al. (2003) The epsilon-sarcoglycan gene (SGCE), mutated in myoclonus-dystonia syndrome, is maternally imprinted. Eur J Hum Genet 11: 138-144.
7. Piras G, El Kharroubi A, Kozlov S, Escalante-Alcalde D, Hernandez L, et al. (2000) Zac1 (Lot1), a potential tumor suppressor gene, and the gene for epsilon-sarcoglycan are maternally imprinted genes: identification by a subtractive screen of novel uniparental fibroblast lines. Mol Cell Biol 20: 3308-3315.
8. Yokoi F, Yang G, Li J, DeAndrade MP, Zhou T, et al. (2010) Earlier onset of motor deficits in mice with double mutations in Dyt1 and Sgce. J Biochem 148: 459-466.
9. Yokoi F, Dang MT, Mitsui S, Li Y, (2005) Exclusive paternal expression and novel alternatively spliced variants of epsilon-sarcoglycan mRNA in mouse brain. FEBS Lett 579: 4822-4828.
10. Ritz K, van Schaik BD, Jakobs ME, van Kampen AH, Aronica E, et al. (2011) SGCE isoform characterization and expression in human brain: implications for myoclonus-dystonia pathogenesis? Eur J Hum Genet 19: 438-444.
11. Tezenas du Montcel S, Clot F, Vidailhet M, Roze E, Damier P, et al. (2006) Epsilon sarcoglycan mutations and phenotype in French patients with myoclonic syndromes. J Med Genet 43: 394-400.
12. Esapa CT, Waite A, Locke M, Benson MA, Kraus M, et al. (2007) SGCE missense mutations that cause myoclonus-dystonia syndrome impair epsilon-sarcoglycan trafficking to the plasma membrane: modulation by ubiquitination and torsinA. Hum Mol Genet 16: 327-342.
13. Ozawa E, Mizuno Y, Hagiwara Y, Sasaoka T, Yoshida M, (2005) Molecular and cell biology of the sarcoglycan complex. Muscle Nerve 32: 563-576.
14. Xiao J, LeDoux MS, (2003) Cloning, developmental regulation and neural localization of rat epsilon-sarcoglycan. Brain Res Mol Brain Res 119: 132-143.
15. Chan P, Gonzalez-Maeso J, Ruf F, Bishop DF, Hof PR, et al. (2005) Epsilon-sarcoglycan immunoreactivity and mRNA expression in mouse brain. J Comp Neurol 482: 50-73.
16. Nishiyama A, Endo T, Takeda S, Imamura M, (2004) Identification and characterization of epsilon-sarcoglycans in the central nervous system. Brain Res Mol Brain Res 125: 1-12.
17. Yokoi F, Dang MT, Zhou T, Li Y, (2012) Abnormal nuclear envelopes in the striatum and motor deficits in DYT11 myoclonus-dystonia mouse models. Hum Mol Genet 21: 916-925.
18. Yokoi F, Dang MT, Yang G, Li J, Doroodchi A, et al. (2012) Abnormal nuclear envelope in the cerebellar Purkinje cells and impaired motor learning in DYT11 myoclonus-dystonia mouse models. Behav Brain Res 227: 12-20.
19. Ichinose H, Ohye T, Takahashi E, Seki N, Hori T, et al. (1994) Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene. Nat Genet 8: 236-242.
20. Knappskog PM, Flatmark T, Mallet J, Ludecke B, Bartholome K, (1995) Recessively inherited L-DOPA-responsive dystonia caused by a point mutation (Q381K) in the tyrosine hydroxylase gene. Hum Mol Genet 4: 1209-1212.
21. Ludecke B, Bartholome K, (1995) Frequent sequence variant in the human tyrosine hydroxylase gene. Hum Genet 95: 716.
22. Asanuma K, Ma Y, Okulski J, Dhawan V, Chaly T, et al. (2005) Decreased striatal D2 receptor binding in non-manifesting carriers of the DYT1 dystonia mutation. Neurology 64: 347-349.
23. Naumann M, Pirker W, Reiners K, Lange KW, Becker G, et al. (1998) Imaging the pre- and postsynaptic side of striatal dopaminergic synapses in idiopathic cervical dystonia: a SPECT study using [123I] epidepride and [123I] beta-CIT. Mov Disord 13: 319-323.
24. Staedt J, Stoppe G, Kogler A, Riemann H, Hajak G, et al. (1995) Nocturnal myoclonus syndrome (periodic movements in sleep) related to central dopamine D2-receptor alteration. Eur Arch Psychiatry Clin Neurosci 245: 8-10.
25. Beukers RJ, Booij J, Weisscher N, Zijlstra F, van Amelsvoort TA, et al. (2009) Reduced striatal D2 receptor binding in myoclonus-dystonia. Eur J Nucl Med Mol Imaging 36: 269-274.
26. Wang Y, Xu R, Sasaoka T, Tonegawa S, Kung MP, et al. (2000) Dopamine D2 long receptor-deficient mice display alterations in striatum-dependent functions. J Neurosci 20: 8305-8314.
27. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG, (1998) Dopamine receptors: from structure to function. Physiol Rev 78: 189-225.
28. Arinami T, Gao M, Hamaguchi H, Toru M, (1997) A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet 6: 577-582.
29. Skidmore F, Reich SG, (2005) Tardive Dystonia. Curr Treat Options Neurol 7: 231-236.
30. Yokoi F, Dang MT, Li J, Li Y, (2006) Myoclonus, motor deficits, alterations in emotional responses and monoamine metabolism in epsilon-sarcoglycan deficient mice. J Biochem 140: 141-146.
31. Zhang L, Shirayama Y, Iyo M, Hashimoto K, (2007) Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine. Neuropsychopharmacology 32: 2004-2010.
32. Sulzer D, (2011) How addictive drugs disrupt presynaptic dopamine neurotransmission. Neuron 69: 628-649.
33. Bello EP, Mateo Y, Gelman DM, Noain D, Shin JH, et al. (2011) Cocaine supersensitivity and enhanced motivation for reward in mice lacking dopamine D2 autoreceptors. Nat Neurosci 14: 1033-1038.
34. Ford CP, Gantz SC, Phillips PE, Williams JT, (2010) Control of extracellular dopamine at dendrite and axon terminals. J Neurosci 30: 6975-6983.
35. Paladini CA, Robinson S, Morikawa H, Williams JT, Palmiter RD, (2003) Dopamine controls the firing pattern of dopamine neurons via a network feedback mechanism. Proc Natl Acad Sci U S A 100: 2866-2871.
36. Wolf ME, Roth RH, (1990) Autoreceptor regulation of dopamine synthesis. Ann N Y Acad Sci 604: 323-343.
37. Schmitz Y, Benoit-Marand M, Gonon F, Sulzer D, (2003) Presynaptic regulation of dopaminergic neurotransmission. J Neurochem 87: 273-289.
38. Magalhaes AC, Dunn H, Ferguson SS, (2011) Regulation of G Protein-Coupled Receptor Activity, Trafficking and Localization by Gpcr-Interacting Proteins. Br J Pharmacol.
39. Bartlett SE, Enquist J, Hopf FW, Lee JH, Gladher F, et al. (2005) Dopamine responsiveness is regulated by targeted sorting of D2 receptors. Proc Natl Acad Sci U S A 102: 11521-11526.
40. Zhang L, Kitaichi K, Fujimoto Y, Nakayama H, Shimizu E, et al. (2006) Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine. Prog Neuropsychopharmacol Biol Psychiatry 30: 1381-1393.
41. Balcioglu A, Kim MO, Sharma N, Cha JH, Breakefield XO, et al. (2007) Dopamine release is impaired in a mouse model of DYT1 dystonia. J Neurochem 102: 783-788.
42. Dang MT, Yokoi F, Cheetham CC, Lu J, Vo V, et al. (2012) An anticholinergic reverses motor control and corticostriatal LTD deficits in Dyt1 DeltaGAG knock-in mice. Behav Brain Res 226: 465-472.
43. Zhang L, Haraguchi S, Koda T, Hashimoto K, Nakagawara A, (2011) Muscle atrophy and motor neuron degeneration in human NEDL1 transgenic mice. J Biomed Biotechnol 2011: 831092.